Effects of Curcumin Supplementation on Clinical Features and Inflammation, in Migraine Patients: A Double‑Blind Controlled, Placebo Randomized Clinical Trial

Migraine is a prevalent health condition associated with significant pain and disability. Neurogenic inflammation has a key role in migraine pathophysiology. Curcumin is a well‑known herb compound with anti‑inflammatory function. This study was aimed to evaluate the effects of curcumin supplementation on clinical features, as well as on serum levels of calcitonine gene‑related peptide (CGRP) and interleukin‑6 (IL‑6).

This randomized double‑blind placebo‑controlled clinical trial was carried out on 44 women with migraine, receiving either 500 mg curcumin twice a day or placebo supplements for 8 weeks. Serum CGRP and IL‑6 concentration, and clinical symptoms including headache severity, duration and frequency were measured at the baseline and end of study.

After 8‑week intervention, compared with placebo, curcumin supplementation led to significand reduction in CGRP (P < 0.001), IL‑6 (P = 0.041), severity (P = 0.001), and duration of headache ( P = 0.007). Headache frequency showed marginal improvement in curcumin group, compared to controls ( P = 0.052). Within‑analysis indicated significant decrease in CGRP and severity (P < 0.001), frequency ( P = 0.014) and duration ( P = 0.003) and no significant decrease in IL‑6 (P = 0.454), compared to baseline in curcumin group. There were no significant changes in body mass index (BMI), weight, percent body fat (PBF), and percent body muscle (PBM) between the two groups.

Curcumin supplementation improved the pro‑inflammatory markers and clinical features of migraine headaches and that could be contributed to could be to its anti‑inflammatory properties.